Oncology Phase 2 Deal Benchmarks (2026)

Median upfront of $258M with total deal values reaching $2.2B.

Median Upfront

$258M

Total Deal Value

$1.6B

Royalty Range

11.8%–19.3%

Territory Multiplier

Understanding Oncology Deal Benchmarks at Phase 2

Phase 2 Oncology licensing deals command a median upfront payment of $258M, with values ranging from $144M at the low end to $365M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.1B to $2.2B, with a median of $1.6B. Royalty rates for oncology assets at this stage typically fall between 11.8% and 19.3% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.

PRO

Full Market Analysis

Detailed deal economics, territory impact analysis, and royalty structure breakdown.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Full Benchmark Data

PRO

Full Benchmark Table

Low, median, and high ranges for upfront payments, total deal values, and royalty rates.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Comparable Deals

Year	Licensor	Licensee	Upfront	Total Value	Deal Type
2023	Daiichi Sankyo	Merck	$4.0B	$22.0B	codevelopment
2023	Daiichi Sankyo	AstraZeneca	$1.0B	$6.9B	codevelopment
2024	Iovance Biotherapeutics	Roche	$150M	$1.2B	collaboration
2023	Seagen	Pfizer	$43.0B	$43.0B	acquisition
2024	ImmunoGen	AbbVie	$10.1B	$10.1B	acquisition
2024	Eisai	Merck	$0M	$5.8B	collaboration
2024	AstraZeneca	Daiichi Sankyo	$2.0B	$6.0B	codevelopment
2023	BMS	N/A (standalone)	$0M	$4.0B	licensing
2024	Genmab	AbbVie	$750M	$3.5B	codevelopment
2024	Syndax Pharmaceuticals	Incyte	$200M	$1.4B	collaboration

PRO

See All Comparable Deals

View 10 comparable Oncology transactions with upfront payments, total values, and deal structures.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Frequently Asked Questions

What is the average upfront payment for Phase 2 Oncology deals?

The median upfront payment for Phase 2 Oncology licensing deals is $258M, based on our analysis of comparable transactions. Values range from $144M for early-stage or less differentiated assets up to $365M for premium programs with strong clinical data or first-in-class mechanisms.

How does Global territory affect Oncology deal value?

Global rights carry a 1x multiplier relative to base deal economics. This means global oncology deals are valued at a discount compared to single-country rights, reflecting the combined market opportunity, regulatory pathway, and competitive dynamics of the territory.

What royalty rates are typical for Phase 2 Oncology licensing?

Royalty rates for Phase 2 oncology assets typically range from 11.8% to 19.3% of net sales. The exact rate depends on the licensor's contribution (IP, clinical data, manufacturing), deal structure (exclusive vs. co-exclusive), and the licensee's commercialization investment. Higher royalties often correspond to lower upfront payments, and vice versa.

PRO

More Expert Insights

Territory impact analysis, royalty negotiation strategies, and deal structure guidance.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

$32M upfront

Oncology · Preclinical · Global

$90M upfront

Oncology · Phase 1 · Global

$721M upfront

Oncology · Phase 3 · Global

$2.1B upfront

Oncology · Approved · Global

$232M upfront

Neurology/CNS · Phase 2 · Global

$547M upfront

Immunology · Phase 2 · Global

$589M upfront

Metabolic/Obesity · Phase 2 · Global

$142M upfront

Oncology · Phase 2 · US Only

Explore More

All Oncology Deals

View full therapeutic area benchmarks

Licensing Benchmarks Guide

2026 data from 1,900+ deals

Royalty Rate Benchmarks

Negotiation strategies by phase & modality

Run Custom Analysis

Pre-filled with Oncology · Phase 2

Run Your Own Benchmark

These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.

Open Deal Calculator

Cite This Data

APA

Ambrosia Ventures. (2026). Oncology Phase 2 Deal Benchmarks (2026). Retrieved from https://calculator.ambrosiaventures.co/data/oncology-phase-2-deals-global

HTML

<a href="https://calculator.ambrosiaventures.co/data/oncology-phase-2-deals-global">Oncology Phase 2 Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)

Embed Chart

Data sourced from 1,900+ verified biopharma transactions. Updated monthly.

Metric	Low	Median	High
Upfront Payment	$144M	$258M	$365M
Total Deal Value	$1.1B	$1.6B	$2.2B
Royalty Rate	11.8%	—	19.3%